Pulse.

a daily field guide to health research that matters

◆ Console

‹ Fri · 13 Nov 2026
Standard addition

Indirect treatment comparisons of nusinersen versus onasemnogene abeparvovec-brve in treatment-naïve and -experienced spinal muscular atrophy patients

Indirect evidence favors one treatment over another for spinal muscular atrophy, though definitive proof awaits direct comparison studies.

Investigators indirectly compared two disease-modifying therapies for spinal muscular atrophy because head-to-head trials are unavailable. Results numerically favored nusinersen, but small effective samples and imprecise estimates require cautious interpretation.

What the study was

Study design
Matching-adjusted indirect treatment comparison of clinical trials
Population
Treatment-naive and treatment-experienced patients with spinal muscular atrophy
Sample size
Effective samples as small as 3 to 58
Category
Treatment Innovation
Maturity
Exploratory
Journal
Journal of medical economics

Why it surfaced

The rare-disease treatment question is important, but indirect comparisons and very small effective samples constrain confidence.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.